Role of diabetes and nitric oxide release duration on analytical performance of in vivo glucose biosensors

 产品说明：本项目的目的是研究在糖尿病猪模型中，释放一氧化氮（NO）的过氧化物植入葡萄糖传感器作为NO释放持续时间的函数的分析性能受益。连续葡萄糖监测（CGM）设备具有优越的上级可用性（即，立即使用和延长持续时间）将大大提高糖尿病患者成功控制其疾病的能力。我们已经在非糖尿病患者中证明了（即，健康）猪模拟NO释放传感器膜，在长达10天内（评价的最长持续时间），既降低了FBR，又促进了分析传感器性能的改善。然而，CGM器械预期用于糖尿病患者，较长的植入时间将提高器械的实用性/价值。健康受试者和糖尿病受试者之间FBR和体内传感器性能的差异目前尚不清楚，但由于生理功能受损和内源性NO产生降低，可能很大。我们假设，我们通过外源性（即，健康动物中的NO释放在糖尿病患者中甚至更大。通过我们的工作，我们将研究延长NO释放对组织生物相容性和传感器性能的影响，作为糖尿病的一个功能。在这方面，我们将产生关于糖尿病如何影响FBR和体内传感器性能的新知识。

 DESCRIPTION: The objective of this project is to study the analytical performance benefits of nitric oxide (NO)-releasing percutaneously implanted glucose sensors in a diabetic swine model as a function of NO-release duration. Continuous glucose monitoring (CGM) devices with superior usability (i.e., for immediate use and extended duration) would greatly increase the ability of those afflicted with diabetes to successfully manage their disease. We have demonstrated in a non-diabetic (i.e., healthy) swine model that NO- releasing sensor membranes both lessen the FBR and facilitate improved analytical sensor performance up to 10 days-the longest duration evaluated. However, CGM devices are intended for diabetic use and longer implantation periods would improve device utility/value. The variance in FBR and in vivo sensor performance among healthy and diabetic subjects is currently unknown but likely large due to impaired physiology and lower endogenous NO production. We hypothesize that the improvements in FBR and sensor performance that we have observed via exogenous (i.e., polymeric) NO release in healthy animals will be even greater in diabetic subjects. Through our work, we will study the influence of extended NO release on tissue biocompatibility and sensor performance as a function of diabetes. In this respect, we will generate new knowledge on how diabetes influences the FBR and in vivo sensor performance.